Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Impact of Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure

Version 1 : Received: 11 April 2024 / Approved: 14 April 2024 / Online: 15 April 2024 (11:36:42 CEST)

A peer-reviewed article of this Preprint also exists.

Nakagaito, M.; Imamura, T.; Ushijima, R.; Nakamura, M.; Kinugawa, K. The Impact of the Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure. J. Clin. Med. 2024, 13, 3196. Nakagaito, M.; Imamura, T.; Ushijima, R.; Nakamura, M.; Kinugawa, K. The Impact of the Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure. J. Clin. Med. 2024, 13, 3196.

Abstract

Background: The clinical impact of withdrawal of sodium-glucose cotransporter 2 inhibitor (SGLT2i) on the all-cause readmission in patients with heart failure remains unknown. Methods: Consecutive 212 patients who were hospitalized for heart failure and received SGLT2i during the index hospitalization between February 2016 and July 2022 were evaluated. Of these, 51 patients terminated SGLT2i during or after their index hospitalization. The primary outcome was defined as an all-cause readmission rates/times. Results: Over a median of 23.2 months, an all-cause readmission occurred in 38 of 51 patients (74.5%) withdrawn from SGLT2i and 93 of 161 patients (57.8%) with continuation of SGLT2i (p = 0.099). The total number of all-cause readmissions per year was 0.97 [0-1.50] in patients withdrawn from SGLT2i and 0.50 [0-1.03] in patients with continuation of SGLT2i (p = 0.030). There was no significant difference in total medical cost (62,906 [502-187,246] versus 29,236 [7,920-180,305] JPY per month, p = 0.866) between both patient groups. Conclusions: Termination of SGLT2i may be associated with incremental all-cause readmission and no benefit in reducing total medical costs.

Keywords

heart failure; SGLT2 inhibitor; hospitalization; medical cost

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.